Evolus Announces Completion Of Phase 2 Study Evaluating "Extra-Strength" Dose Of Jeuveau; Presentation Of The Full Dataset Will Be Planned For A Medical Meeting In Q4 2023
Portfolio Pulse from Benzinga Newsdesk
Evolus has completed its Phase 2 study evaluating the extra-strength dose of Jeuveau, with the full dataset presentation planned for a medical meeting in Q4 2023.
June 22, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evolus has completed the Phase 2 study for the extra-strength dose of Jeuveau, which may positively impact the company's stock in the short term.
The completion of the Phase 2 study for Jeuveau's extra-strength dose indicates progress in the product's development. This news may be seen as a positive milestone for investors, potentially leading to a short-term increase in Evolus' stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100